Plain-English translation of NCT07633626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether vortioxetine, an antidepressant medication, can help reduce thinking and memory problems that some patients experience while taking lorlatinib for a specific type of lung cancer. About 4 in 10 patients on lorlatinib develop cognitive side effects like trouble concentrating or mood changes, and this medication may help. Researchers will track your thinking abilities, mood, and quality of life over 6 months to see if this treatment helps.
Lorlatinib is a highly effective lung cancer drug, but it can cause thinking problems, memory issues, and mood changes in many patients. This study exists to see whether adding an antidepressant medication can reduce these side effects and help patients maintain their quality of life during cancer treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the medication as prescribed by your doctor while continuing your regular cancer treatment. You'll visit the research team at baseline and then at 6 weeks, 12 weeks, and 6 months after starting the medication. At each visit, you'll complete thinking and memory tests, answer questions about your mood and quality of life, and discuss any side effects with the research team. The entire study lasts about 6 months.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Colombia